Patents Examined by Maury Audet
  • Patent number: 10927188
    Abstract: Provided is a method for producing a short-chain peptide-immobilized carrier that maintains a secondary structure of a short-chain peptide, the method including a step of preparing an alcohol solution containing an alcohol solvent, and a short-chain peptide having a plurality of immobilizing functional groups, the short-chain peptide having a secondary structure induced in the alcohol solvent; and a step of bringing a carrier coupled with a spacer having a reactive group that reacts with the immobilizing functional group, into contact with the alcohol solution, and thereby immobilizing the short-chain peptide to the spacer.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: February 23, 2021
    Assignee: FUJIFILM Corporation
    Inventor: Koichi Minami
  • Patent number: 10927144
    Abstract: Methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant are described, which methods comprise the sequential steps of: (a) passing the composition through an ion exchange membrane, where the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pI of the polypeptide to enhance the charge of the polypeptide and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the polypeptide and the at least one contaminant, and (b) recovering the purified polypeptide from the effluent.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: February 23, 2021
    Assignee: GENENTECH, INC.
    Inventors: Arick Brown, Jerome Bill, Jr., Timothy Tully, Christopher Dowd
  • Patent number: 10927152
    Abstract: Provided are astexin-1, astexin-2 and astexin-3 lasso peptides, which are based on sequences identified in Asticcacaulis excentricus, and methods of making and using same. Astexin-1 is highly polar, in contrast to many lasso peptides that are primarily hydrophobic, and has modest antimicrobial activity against Caulobacter crescentus, a bacterium related to Asticcacaulis excentricus. The solution structure of astexin-1 was determined, revealing a unique topology that is stabilized by hydrogen bonding between segments of the peptide. Astexins-2 and -3 are intracellular lasso peptides.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: February 23, 2021
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: A James Link, Mikhail O. Maksimov
  • Patent number: 10918727
    Abstract: Disclosed are a translationally controlled tumor protein derived-protein transduction domain (TCTP-PTD) having the ability to penetrate the cell membrane, and to the use thereof. The TCTP-PTD peptide is capable of improving the ability of a target substance to penetrate the cell membrane to thereby effectively deliver the target substance into a living body, including cells, tissue and blood. Thus, the TCTP-PTD peptide may be used for research purposes in vitro, and may be used for clinical purposes, including treatment of various diseases, delivery of contrast agents, etc., and may also be used for diagnostic purposes and in cosmetic applications.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 16, 2021
    Assignee: ICURE BNP CO., LTD.
    Inventors: Kyung Lim Lee, Hea Duk Bae, Jee Hye Maeng
  • Patent number: 10919940
    Abstract: The present disclosure generally relates to a circularized peptide for treating cancer. An cyclic peptide is disclosed that has an amino acid sequence selected from Lys-X5-Glu-X1-X2-Gln-Met-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 3), (SEQ ID NO: 4), Lys-Gly-X6-Val-Leu-Gln-Met-X7-X8-X9-Leu-Val (SEQ ID NO: 5), Lys-X5-Glu-X1-X2-Gln-X12-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 9), and X10-X5-X6-Val-Leu-Gln-Met-Glu-Asp-X9-X3-X4 (SEQ ID NO: 10). The amino acids X1, X2, X3, and X4 can be each independently valine, leucine, isoleucine, or alanine; X5 can be glycine, alanine, leucine, isoleucine, or valine; X6, X7, X8, and X9 can be each independently glutamic acid or asparagine; X10 can be lysine or arginine; X11 can be methionine or cysteine; and X12 can be methionine or norleucine. The cyclic peptide can have the amino acid sequence Lys-Gly-Glu-Val-Leu-Gln-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 1).
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: February 16, 2021
    Assignee: Saint Leo University
    Inventor: Sergiy I. Borysov
  • Patent number: 10919934
    Abstract: This disclosure relates to compositions for use in managing respiratory distress and related disorders. In certain embodiments, the disclosure relates to methods of treating or preventing respiratory distress comprising administering an effective amount of a pharmaceutical composition comprising peptides or agents disclosed herein to a subject in need thereof. In certain embodiments, the peptides or agents decrease the concentration of claudin-5 in cells and tissues of the lungs.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: February 16, 2021
    Assignee: Emory University
    Inventors: Michael Koval, Barbara Schlingmann
  • Patent number: 10918730
    Abstract: Described herein are bioactive peptides that are modified at one or more positions with a PEG moiety. An example of such a PEGylated bioactive peptide is a GHRH analog that is modified at one or more positions with a PEG moiety. Also described are pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such analogs or salts thereof, as well as methods, kits and uses thereof, for example for inducing or stimulating growth hormone secretion in a subject and for diagnosing, preventing or treating GH-deficient conditions in a subject.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: February 16, 2021
    Assignee: GRIFFON PHARMACEUTICALS INTERNATIONAL SA
    Inventor: Krishna G. Peri
  • Patent number: 10913771
    Abstract: Provided is a novel peptide for preventing or treating inflammatory diseases and a use thereof. According to the novel dimeric or trimeric peptide, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances. Therefore, it is expected that the peptide can be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: February 9, 2021
    Assignee: KINE SCIENCES CO., LTD.
    Inventors: Dae Ho Cho, Kyung Eun Kim, Sun Young Park, Myung Jin Jung, Joo Hyun Lee
  • Patent number: 10913772
    Abstract: Provided is a peptide for preventing or treating inflammatory diseases and a use thereof. According to a novel dimeric peptide according to the present invention, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances and will be expected to be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: February 9, 2021
    Assignee: KINE SCIENCES CO., LTD.
    Inventors: Dae Ho Cho, Kyung Eun Kim, Sun Young Park, Youn Kyung Houh
  • Patent number: 10899822
    Abstract: Compositions are disclosed that include D-amino acid peptides and that are capable of specifically binding to at least one autoantibody against a G-protein coupled receptor. The autoantibody is produced in a patient having or being predisposed to a disease, condition, or disorder, and the autoantibody is capable of binding to a specific epitope of the G-protein coupled receptor. Methods of production and use of said compositions are also disclosed.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: January 26, 2021
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: David C. Kem
  • Patent number: 10900027
    Abstract: During the process of coagulation, prothrombin is activated to ?-thrombin by prothrombinase. Key residues in the structure of prothrombin allow for modulation of the activation of prothrombin. In certain embodiments, a recombinant prothrombin with at least one point mutation or deletion is provided.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: January 26, 2021
    Assignee: Cleveland State University
    Inventors: Michael Kalafatis, Joseph Wiencek
  • Patent number: 10866249
    Abstract: The present application relates to methods of treating HIV-associated nephropathy (HIVAN) and/or focal segmental glomerulosclerosis (FSGS) using endothelin-1 (ET-1) antagonists. The application further relates to a composition for the treatment of HIVAN and/or FSGS. A kit for detecting the presence of ET-1 or ET-1-associated biomarker in a biological sample is also disclosed.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: December 15, 2020
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Gale W. Newman, Barbara A. Jacob-Mungin, Chamberlain Obialo
  • Patent number: 10851134
    Abstract: A method for preparing a cyclopeptide, which includes the following steps: (A) providing compounds represented by the following formulas (II-1) or (II?-1) and (II-2); (B) performing a reaction between the compounds of formulas (II-1) or (II?-1) and (II-2), to obtain a compound represented by the following formula (II-3) and (II?-3), respectively; (C) performing a reaction between the compound of formula (II-3) or (II?-3) and a compound represented by the following formula (II-4) or (II?-4), respectively, is performed, to obtain a compound represented by the following formula (II-5), and (II?-5), respectively; (D) performing a cyclization reaction of the compound of formula (II-5) or (II?-5) with a catalyst of formula (III), to obtain a compound represented by the following formula (I) or (I?), respectively. The formulas (I), (I?), (II-1) to (II-5), (II?-1) to (II?-5) and (III) are shown in the specification.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: December 1, 2020
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventor: Chien-Tien Chen
  • Patent number: 10828372
    Abstract: Described herein is a mono-end PEGyated functional upstream domain (FUD), pharmaceutical compositions, and its use to inhibit fibrosis such as organ fibrosis, idiopathic pulmonary fibrosis and fibrosis associated with cancer. Also included are methods of probing for injured or repairing tissue in an individual in need thereof using the mono-end PEGyated-FUD.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: November 10, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Bianca R. Tomasini-Johansson, Glen S. Kwon, Pawel Waldemar Zbyszynski, Nathan Sandbo, Ksenija Bernau
  • Patent number: 10816547
    Abstract: The present invention relates to compositions which may comprise a non-naturally occurring or engineered artificial transcription factor, wherein the transcription factor may comprise a sequence specific DNA binding domain, a sliding domain, and one or more linkers, wherein the DNA binding domain and the sliding domain are operably connected by the one or more linkers, and uses thereof. Methods involving the use of a non-naturally occurring or engineered artificial transcription factors and pharmaceutical compositions, methods for treating cancer, a degenerative disease, a genetic disease or an infectious disease as well as diagnostic methods are also contemplated by the present invention.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: October 27, 2020
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Paul Blainey, Anthony Kulesa, Kan Xiong
  • Patent number: 10813858
    Abstract: A cosmetic composition is provided, the composition comprising a safe and effective amount of a skin care active with A log P less than ?2.0, a safe and effective amount of a fatty alcohol; and a safe and effective amount of a glyceryl ester. The combination of fatty alcohol and glyceryl esters surprisingly enhances penetration of skin care actives with low A log P values into skin.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: October 27, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Kunal Virendra Gujraty, Shikhar Gupta, Yan Yan, Naohisa Yoshimi
  • Patent number: 10815282
    Abstract: The disclosure of the present application relates to a secretory deleted split hand/split foot 1 (sDSS1) protein, the amino acid sequence thereof, the nucleic acid sequence thereof, and the applications of the same. The sDSS1 protein is a secretory protein from higher primate, and can be detected in human serum and cerebral spinal fluid (CSF). The sDSS1 protein can form conjugate with oxidized protein under nonenzymatic condition or with amyloid-beta (A?) polypeptide to reduce formation of A? oligomer. The addition of sDSS1 protein to culture medium can shield the cytotoxicity induced by oxidized protein, A? oligomer, amylin oligomer and glycosylated protein, so as to protect the cells against these toxoproteins. The sDSS1 protein can prolong survival time of senescence-accelerated mice significantly.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: October 27, 2020
    Assignee: Shanghai Clear Fluid Biomedical Science Co., Ltd.
    Inventors: Yinghao Zhang, Jingpeng Fu, Jia Wan
  • Patent number: 10800827
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 13, 2020
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Patent number: 10765748
    Abstract: In various aspects, embodiments of the present invention are directed to a series of multivalent dendrons containing a bioactive peptide domain and surface-binding catechol domains. In some embodiments, these multivalent dendrons were obtained through solid phase synthesis and have a strong binding affinity to metal oxide surfaces such as, TiO2, ZrO2, CeO2, and Fe3O4, SiO2, as well as other inorganic surfaces such as hydroxyapatite, silver, fluorapatite, calcium carbonate and gold. These catechol-bearing dendrons provide a fast and efficient method to functionalize a wide range of inorganic materials with bioactive peptides and have the potential to be used in coating orthopaedic implants and fixation devices.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: September 8, 2020
    Assignee: University of Akron
    Inventors: Matthew Becker, Wen Tang
  • Patent number: 10745737
    Abstract: Methods, reagents, and kits for the reversible immobilization of glycoproteins to a solid support, the release and capture of a glycan portion of the glycoprotein, and the subsequent release and capture of the polypeptide portion of the glycoprotein are provided. The disclosure also provides suitable solid support materials, surface chemistries, and devices for use in the disclosed methods. The methods, reagents, kits, and devices provided herein are useful for the analysis of protein glycosylation, for example, in a diagnostic context, in the context of proteoglycomics, and in the context of producing glycosylated proteins for therapeutic purposes.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: August 18, 2020
    Assignee: Children's Medical Center Corporation
    Inventors: Richard S. Lee, Hui Zhou